| EMA number | EMEA/H/C/000972 |
| ATC code | L01XC09 |
| Authorisation | 20 April 2009 |
| Withdrawn | 2 June 2017 |
| Revision | 5 |
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.